MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug.
about
Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesisRole of microRNAs in hepatocellular carcinoma: a clinical perspectiveIdentification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMTPolymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferationSerial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines.Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues.An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy.Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics.Screening for characteristic microRNAs between pre-invasive and invasive stages of cervical cancer.A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells.A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesisDown-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancerThe overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells.Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.Potential clinical insights into microRNAs and their target genes in esophageal carcinoma.MicroRNA replacement therapy for cancer.The role and clinical implications of microRNAs in hepatocellular carcinoma.DNA methylation and cancer development: molecular mechanism.MicroRNAs in gastrointestinal cancer: prognostic significance and potential role in chemoresistance.MicroRNA theragnostics for the clinical management of multiple myeloma.Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities.Enhancing identification of cancer types via lowly-expressed microRNAs.Single cell biology beyond the era of antibodies: relevance, challenges, and promises in biomedical research.Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis.Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer.Epigenetic changes in colorectal cancerMicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression.Computational analysis of siRNA recognition by the Ago2 PAZ domain and identification of the determinants of RNA-induced gene silencing.Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors.MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop.Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential.LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.MicroRNA and cancer.MiR-338-3p inhibits TNF-α-induced lipogenesis in human sebocytes.A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer.
P2860
Q26783563-51E81DDD-D208-408B-9A4A-A4E7CA97D776Q27014034-22DF76D3-A5C9-43D6-B50A-98AFD8959C48Q28744173-5CAECC5E-CA1E-4F69-BAC8-945A0A757B4CQ30632163-82D4813D-DB0F-4D90-B9D7-BA9ADB8DFE65Q33780027-E915CA55-9E1F-4C65-B310-D862D6531E03Q34226918-BDC13F25-0582-4903-8EBA-76D0F022C1E5Q34428112-9C3D76D3-2079-4C53-BECB-7862F9220CF1Q34478571-A516969D-9324-4C02-A131-C74C28C87F7DQ35565247-914F6135-E1CF-4958-A2D9-82395AF97221Q35628464-969CB598-49AC-48E3-8F11-4A8A3E41145EQ35931759-E969408D-065B-421F-9B85-9DB2A274628CQ35997446-FCF6F0FE-CA18-4585-93A8-A0191140C3FCQ35998435-468BB404-4AEF-4786-8771-53F090096E32Q36779495-81BC8CB8-F261-4D3D-8294-B32A09265D3BQ37113195-F36732C3-6A15-4883-890F-C336E93D242EQ37190159-E9B81244-8B73-484F-BC05-08478190E8F6Q37922792-47308D3C-D4CA-402C-A24C-A42EA4802377Q37924177-86054DC7-A993-454A-9C68-31BB0E9E1540Q38056415-E9A9048F-07BC-4B7C-8516-4292FC9996F4Q38091024-50CCDCF3-F2AA-4E24-81AF-829EFE13AA62Q38202662-1C8936CF-CF03-4FA2-9A4A-515751829C53Q38203140-BADB6B30-5D90-4187-BC4F-B2A9D0913A6AQ38826542-3A08B70E-61A7-436A-8D0E-AB10DA3BEFA3Q38843518-8D128271-68C0-4048-AC37-0FB227EA167EQ38853181-E6BFC622-B8D0-47D8-B0CD-6A0787D38D6EQ38974617-CA6EA00F-69E8-4509-8083-6B9B39EEA226Q38988230-9B81E5A5-6ED2-42C7-8969-69BBE6DC4925Q39091201-9476DAE1-E593-400D-B1B1-3B60A8BACEB1Q41973340-CAA3F060-0FD0-48F6-84B3-A5924E4D06F7Q41974673-EC41E31E-399E-4C4D-8B19-99A543780CB4Q42114819-2CB965F5-F3B3-4A23-943D-EEC857046725Q43715641-007AF3E6-8538-4A6B-B3AD-F8ADF2278DD2Q45854086-044CE33F-C67F-4ECF-98F0-A48062B2A0ABQ45960821-734539E6-1C37-43FF-B59F-54D8A681F9D9Q47295997-A98C794C-A7D0-4CFB-B88A-829403C400FEQ47994022-44E8E727-EAF4-4664-8350-EDFA12AD2831Q50927478-85963EE2-C617-4848-AC93-C205E11DFC62Q53137197-33F9DBD3-FFE0-402E-9A5F-55E333C030DAQ53775019-42A50A94-2C55-43A2-8E7A-777FC04CBEBDQ55260348-3B8B9C55-AA42-4F14-9E23-20A476455A0D
P2860
MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@ast
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@en
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@nl
type
label
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@ast
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@en
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@nl
prefLabel
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@ast
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@en
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@nl
P356
P1476
MicroRNAs and their therapeuti ...... iR-143 as an anti-cancer drug.
@en
P2093
Yukihiro Akao
Yukio Kitade
P304
P356
10.1254/JPHS.10R12FM
P577
2010-10-09T00:00:00Z